Brii Biosciences Limited

Brii Biosciences Limited

Brii Biosciences is a biotechnology company founded to address public health challenges through scientific innovation. The firm operates with offices in Nashville, Beijing, San Francisco, and New York, though its founding principal and wealth origin are not publicly disclosed. The company builds a pipeline targeting infectious diseases and central nervous system disorders, areas it identifies as having high unmet medical needs. Its lead program includes BRII-179, an investigational therapy for hepatitis B. At the EASL Congress 2026, Brii presented late-breaking data from its Phase 2 ENSURE study evaluating BRII-179's potential to achieve durable immunological control of HBV (per company press release, May 2026). The firm also presented a cross-study analysis of post-treatment HBsAg rebound at APASL 2026 (per company press release, April 2026). Pipeline focus includes first-in-class and different-in-class treatment options. As of mid-2026, the company has not disclosed its total deployment, AUM, or team size. Recent operational highlights include multiple data presentations at major hepatology conferences in 2026, signaling continued clinical development activity. No additional offices beyond the four cities have been confirmed. A notable structural feature is the firm's narrowed mandate on two disease areas — infectious disease and CNS — where social stigma and limited treatment choice drive patient need. This focus contrasts with broader biotech platforms, aiming for targeted impact in under-served populations.